Trials / Recruiting
RecruitingNCT06733441
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Phase 1b, Randomized, Dose Optimization Study to Assess the Anti-Tumor Activity, Safety, and Pharmacokinetics of TLN-254 in Patients With Relapsed or Refractory T-cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Treeline Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLN-254 | TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation. |
| DRUG | TLN-254 | TLN-254 will be administered orally at a specified dose on specified days. |
Timeline
- Start date
- 2024-12-16
- Primary completion
- 2026-11-15
- Completion
- 2028-11-15
- First posted
- 2024-12-13
- Last updated
- 2025-10-10
Locations
5 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06733441. Inclusion in this directory is not an endorsement.